Boston Scientific Corp (BSX)

[Penny Roger$]

~ Thursday! $BSX ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $BSX ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=BSX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=BSX&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=BSX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=BSX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=BSX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=BSX
Finviz: http://finviz.com/quote.ashx?t=BSX
~ BusyStock: http://busystock.com/i.php?s=BSX&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=BSX >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[j smoo]

Boston Scientific to Announce First-Quarter 2012 Financial Results on April 19
1 days 18 hours 28 minutes ago - PR Newswire via Comtex
Boston Scientific Corporation (NYSE: BSX) announces it will webcast its first-quarter 2012 financial results conference call on Thursday, April 19, at 8:00 a.m. Eastern Time.

The call will be hosted by Hank Kucheman, chief executive officer, and Jeff Capello, executive vice president and chief financial officer.

A live webcast of the conference call will be available via Boston Scientific's website. Webcast registration is available on the Investor Relations section of the website at www.bostonscientific.com/investors. Interested parties are encouraged to register at least 15 minutes prior to the scheduled start time to ensure a timely connection.

The webcast is also being distributed over Thomson Reuters Investor Distribution Network via two locations: www.earnings.com, which is accessible to the public, and www.streetevents.com, a password-protected event management site.

An archived replay of the webcast will be accessible at www.bostonscientific.com/investors approximately one hour following the completion of the conference call and available for approximately one year.

The Company will issue a press release announcing first-quarter 2012 financial results prior to the conference call on Thursday, April 19.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

CONTACT:

Steven Campanini508-652-5740 (office)Media RelationsBoston Scientific Corporation [e-mail]

Sean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporation [e-mail]

SOURCE Boston Scientific Corporation

[ek70]

With all that BSX has going for itself, JNJ is posied to acquire them soon.

[lazyeye]

Great news lately on the industry as a whole..$6.00+ soon? Hmm...

[mlkrborn]

Boston Scientific WallFlex Enteral Stents shown to be safe and effective in three clinical registries (BSX) 6.02 : Co sees 'positive' results from three studies of the WallFlex Enteral Stent Systems, a family of self-expanding metal stents (SEMS) used to alleviate obstructive symptoms caused by cancers of the gastrointestinal tract. The studies, published in peer-reviewed medical journals, determined the WallFlex Stents to be safe and effective for the treatment of malignant colorectal and gastroduodenal obstruction.

* The first publication appeared in the October 2011 issue of Gastrointestinal Endoscopy, and reported the short-term safety and effectiveness of the Boston Scientific WallFlex Enteral Colonic Stent for relieving malignant colorectal obstruction. The WallFlex Enteral Colonic Stent was determined to be safe and effective for treatment of malignant colorectal obstruction with a clinical success rate of 90.5 percent.
* The second publication, appearing in the December 2011 issue of The American Journal of Gastroenterology, show rates of 97.8 percent procedural success and 94 percent clinical success, prompting the authors to conclude that the WallFlex Colonic Stent is both safe and effective as a bridge-to-surgery treatment in patients with acute malignant obstruction.
* The third publication in the January 2012 issue of Digestive and Liver Disease shows procedural and clinical success rates of 98 and 91 percent respectively. The authors concluded that adoption of duodenal stenting could result in this minimally invasive procedure becoming standard of care when managing inoperable patients with advanced cancer experiencing gastric outlet obstruction.

[Penny Roger$]

~ $BSX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $BSX ~ Earnings expected on Thursday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=BSX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=BSX&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/BSX?
~ OTC Markets: http://www.otcmarkets.com/stock/BSX/company-info
~ Google Finance: http://www.google.com/finance?q=BSX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=BSX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=BSX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=BSX
Finviz: http://finviz.com/quote.ashx?t=BSX
~ BusyStock: http://busystock.com/i.php?s=BSX&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=BSX&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=BSX
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=BSX
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=BSX
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=BSX
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=BSX
~ MarketWatch: http://www.marketwatch.com/investing/stock/BSX/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=BSX
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=BSX
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=BSX&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=BSX&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=BSX&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[mlkrborn]

Boston Scientific announces FDA approval of the Infinion 16 Percutaneous Lead for its Precision Plus Spinal Cord Stimulator System (BSX) 5.59 :

[SAE]

Boston Scientific Introduces Industry-Leading ICD and CRT-D Device Warranties

Boston Scientific Corporation (NYSE: BSX) announced that, along with today's introduction of a new family of INCEPTA™ and ENERGEN™ implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), it is providing an extended warranty for these devices in the U.S. and many international countries of up to 10 years, depending on model.(1) The new warranty is up to five years longer than other currently marketed devices.

"Our clinical data show that the majority of patients who have ICDs live more than seven years after implant, and some live for decades," said Robert Hauser, M.D., Minneapolis Heart Institute, Abbott Northwestern Hospital. "The excellent longevity of these devices combined with the length of the warranty has both clinical and financial implications for patients. Greater longevity potentially reduces the number of implant surgeries, which minimizes complication risk and helps improve patient outcomes. The warranty also reduces out-of-pocket expenses for patients as well as healthcare system costs."

"Offering the industry's longest warranty for these ICDs and CRT-Ds, in conjunction with the lifetime warranty for our ICD leads, reflects our confidence in the quality, durability and longevity of our entire device system," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Cardiac Rhythm Management Group. "Creating longer-lasting devices is simply the right thing to do for patients. It benefits those who are living longer due to advances in device therapy, those who are receiving devices earlier in their lives based on our clinical science, and those who need more frequent device changes because of their clinical condition."

"We have made significant investments in advanced battery technology that now has projected device longevity of up to 10 years, far outpacing our competitors," said Mike Mahoney, President of Boston Scientific. "We are now backing this longevity with the longest warranty in the industry to support these next-generation devices designed to save and enhance the lives of patients experiencing heart failure and sudden cardiac death."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches, clinical trials, product performance, product warranties and their effects and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; product performance; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) ENERGEN & INCEPTA VR ICD - 10 years; ENERGEN & INCEPTA DR ICD - 8 years; ENERGEN & INCEPTA CRT-D - 6 years.




CONTACT:


David Knutson






651-260-8288 (office)






Media Relations






Boston Scientific Corporation






[e-mail]











Sean Findlen






617-520-7268 (office)






Media Relations






Weber Shandwick






[e-mail]











Sean Wirtjes






508-652-5305 (office)






Investor Relations






Boston Scientific Corporation






[e-mail]







SOURCE Boston Scientific Corporation

[SAE]

Boston Scientific Announces FDA Approval and First Implant for New Devices to Treat Heart Failure and Sudden Cardiac Death

Boston Scientific Corporation (NYSE: BSX) announces FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) to treat heart failure and sudden cardiac death. The new devices offer enhanced therapy options, advanced battery longevity and a DF4 universal connector system in the industry's smallest and thinnest platform. The first implant of the Company's next-generation INCEPTA ICD occurred yesterday at the University of Washington Medical Center in Seattle by Jeanne E. Poole, M.D., FHRS, FACC, Professor of Medicine and Director, Arrhythmia Service and Electrophysiology Laboratory.

To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/43511-boston-scientific-fda-approval-incepta-energen-punctua-heart-cardiac

(Photo: http://photos.prnewswire.com/prnh/20111130/MM12324)

"Boston Scientific is providing physicians a choice of premium high-energy devices that are the world's smallest and thinnest, offer advanced battery technology with excellent longevity, and are backed by the longest warranty in the industry of up to 10 years," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Cardiac Rhythm Management Group. "This new portfolio of products, built on our tradition of innovation, will provide physicians with flexible therapeutic options designed to match specific patient needs."

"These devices are a direct response to what patients tell us they want the most -- small, thin, long-lasting devices that provide appropriate therapy when necessary," said Dr. Poole. "Additionally, these devices are designed to streamline the implant procedure with Boston Scientific's 4-SITE™ DF4 connector system."

"The DF4 connector system makes the industry's smallest devices even smaller, potentially increasing patient comfort and making the implant procedure quicker and easier for physicians, while the new features will offer even more options for customizing patient care," said Kenneth Stein, M.D., Chief Medical Officer of Boston Scientific's Cardiac Rhythm Management Group. "The 4-SITE lead is built on the RELIANCE® family of defibrillation leads, which has a demonstrated survival probability of 99 percent at seven years."

The 4-SITE DF4 connector system reduces the volume of Boston Scientific's single-chamber ICDs to 30.5cc and CRT-Ds to 32cc, while maintaining a thickness of less than 10mm. The system is also designed to simplify and reduce the time needed for the implant procedure by combining three separate lead terminals into one integrated connection and leveraging the new EZ-4™ Connector Tool which allows physicians to reduce the number of steps required during implant.

These next-generation devices also include options to promote appropriate therapy, reduce right ventricular pacing, and improve patient management through the availability of the LATITUDE® Heart Failure Management weight scale and blood pressure cuff sensors.

"Including remote monitoring as a standard for patients will assist physicians involved in the management of this very complex disease. By involving patients in that process, it could also motivate them to become more engaged in their own care," said Leslie A. Saxon, M.D., Chief of Cardiovascular Medicine at University of Southern California, and Committee Chair of the ALTITUDE Clinical Program sponsored by Boston Scientific. "In the ALTITUDE Survival study, patients with remote monitoring had a lower mortality rate."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches, regulatory approvals, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:
David Knutson

651-260-8288 (office)

Media Relations

Boston Scientific Corporation

[e-mail]


Sean Findlen

617-520-7268 (office)

Media Relations

Weber Shandwick

[e-mail]



Sean Wirtjes

508-652-5305 (office)

Investor Relations

Boston Scientific Corporation

[e-mail]

SOURCE Boston Scientific

[gojoe83]

Big week coming for BSX see a nice spike this coming week Keep an eye on

[PumpKiller]

Yeah I agree, something holding it back, maybe market maker is in on this, maybe they don't want it to run yet, it always been more buys than sell but would never pop.

BSX was purchased by one insider during the past month. Ernest Mario bought 25,000 shares at $5.45 on October 26. A day earlier, Mario bought another 25,000 shares at $5.5. The stock is now trading at $5.3. It has a market cap of $7.9B, a P/E ratio of 14.32, and lost 29.99% so far this year. Leon Cooperman invested nearly $100 million in BSX.

So the chit has to move up soon, I got CALL for $6 Jan on this baby
Hopefully it start to run soon.

[DERBYBLOOD]

What's wrong with this POS ? FDA Approval and only a tiny pop, then flat?

[mlkrborn]

Boston Scientific receives FDA approval for PROMUS Element plus platinum chromium stent system (BSX) 5.31 : The co expects to record a pre-tax charge of ~$40 mln ($35 mln after-tax) during the fourth quarter of 2011 as a result of the early approval and launch timing of the PROMUS Element Plus Stent System in the U.S. primarily related to inventory reserves which will impact gross margins. This charge was not included in the co's previously issued financial guidance for the fourth quarter.

[sportodc]

FDA Approves New Boston Scientific Heart Stent
Last update: 11/22/2011 7:29:13 PM

[lazyeye]

Ernie Mario (Director) sunk almost $700K personal funds into this in August, buying at $6.82/share...

Crappy economy and yet this co still doing ok...

Maybe a buyout looms?

Cheap price here imo...looking for a bounce soon...

[mlkrborn]

Boston Scientific beats by $0.06, misses on revs; guides Q4 EPS above consensus, revs below consensus; repurchased 30 mln shares (BSX) 5.64 : Reports Q3 (Sep) earnings of $0.15 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus Estimate of $0.09; revenues fell 2.2% year/year to $1.87 bln vs the $1.91 bln consensus. Co issues mixed guidance for Q4, sees EPS of $0.13-0.16 vs. $0.10 Capital IQ Consensus Estimate; sees Q4 revs of $1.85-1.95 bln vs. $1.97 bln Capital IQ Consensus Estimate. Compared to sales for the fourth quarter of 2010, this range assumes a $64 million negative impact from the divestiture of the Neurovascular business. Recent acquisitions are not expected to contribute significantly to fourth quarter sales. Recent acquisitions are expected to dilute fourth quarter 2011 adjusted earnings by ~$0.01 per share as compared to the prior year, and the divestiture of the Neurovascular business is expected to dilute fourth quarter 2011 adjusted earnings by $0.01 per share. Co also announced that they invested $192 mln to purchase 30 mln shares under the co's estimated $1.25 bln combined share repurchase authorizations.

[mlkrborn]

BSX 5.85 after getting rid of Guidant's headache/.
DOJ: Boston Sci's Guidant Agrees To Pay $9.3M To Settle Claims
Last update: 9/26/2011 3:11:57 PM
DOW JONES NEWSWIRES
The U.S. Department of Justice said Boston Scientific Corp.'s (BSX) Guidant subsidiary agreed to pay $9.3 million to settle the government's allegations that it inflated the cost of replacement devices to federal health-care programs.
Representatives for Boston Scientific were unable to comment immediately on the news.
Boston Scientific bought implantable defibrillator maker Guidant for $28.4 billion in 2006 but has struggled to make the costly acquisition pay off.
The Justice Department had claimed that Guidant inflated the cost of replacement pacemakers and defibrillators to federal health care programs by failing to grant warranty credits and rebates to hospitals for devices that were taken out while covered by some sort of warranty or credit program.
Monday's civil settlement resolves allegations contained in a whistleblower lawsuit. As part of the resolution, whistleblower Robert A. Fry will receive payments of more than $2.3 million from the settlement amount.
Shares in Boston Scientific were up 2.1% at $5.88 in recent trading.
-By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; [e-mail]
(END) Dow Jones Newswires

[conix]

Medical Device Companies May Have Eyes On Non-Invasive Alternative Technology

Seeking Alpha

September 15, 2011 | about: CTTC.PK, includes: BSX, MDT, SYK


Calmare(R) is a non-invasive and non-narcotic chronic pain management therapy that has benefited many patients who have reported that their pain scale (VAS) number was reduced significantly, often down to "pain free" or "0," with those results lasting for months. And the technology is beginning to gain traction in the marketplace. It is one thing to see a small company making headway in a huge market and quite another when considering that larger medical device companies in the pain management sector could be interested in adding a non-invasive and non-narcotic alternative to their portfolio of pain management therapies. Boston Scientific Corporation (NYSE:BSX), Stryker Corporation (NYSE:SYK) and Medtronic, Inc. (NYSE:MDT) all offer an invasive and expensive pain therapy using spinal implants and they have done well in the marketplace. Significantly, all the aforementioned companies have a history of acquiring new technologies.

The surgical alternative therapies for chronic pain offered by BSX, SYK and MDT are usually reimbursed by private insurance and Medicare. The implants enable the patients to control the intensity of electrical current for their own pain relief. Usually spinal implants are not advised for chronic pain patients until all other therapies have been exhausted and proven to be ineffective for a particular patient. In addition, the use of medications has come under increasing scrutiny due to their inherent addictive properties. So non-invasive pain medications can have a significant downside in the treatment of pain and can have a reduced effect over time with many patients.

It is well accepted in the chronic pain management discipline that conventional transcutaneous electrical nerve stimulation (TENS) units do not provide long-term pain relief. But in the middle ground between non-invasive TENS and invasive surgical implants is a new technology - Calmare technology - which, depending on the pain condition and the individual patient, can provide long-term relief or reduction of neuropathic pain without surgery.

Competitive Technologies (CTTC.PK) is the company with that potentially groundbreaking technology (technical details are accessible at calmarett.com).

Sporting a capitalization of only $18.9 Million (currently trading at $1.38/share), Competitive Technologies (CTTC.PK) is the licensed worldwide distributor of the non-invasive Calmare(R) pain therapy medical device (also known as MC-5A and/or "Scrambler Therapy"). On August 18, the company announced its first order from the US military--the sale of 12 Calmare units to be installed in nine U.S. military medical facilities in the U.S. and overseas (including Camp Pendleton, Camp LeJeune, and the Bethesda Medical Center).
Click HERE for the full list of military locations.

The military had conducted an evaluation of Calmare at a number of military hospitals for over a year resulting in an initial order from the Federal Government. As a frame of reference for the potential for additional Calmare placements, there are 1748 Veterans Administration (VA) hospitals and 266 Department of Defense (DOD) medical centers that could employ Calmare in their chronic pain management therapy regimen. Considering the Federal budget deficit problem, any technology that may provide a lower cost solution to chronic neuropathic pain will most likely be explored. BSX, MDT and SYK spinal implants are already being used within the US Military system.

Technology Already Approved for Sale

Unlike many small medical device companies preparing to go through the FDA approval process before the company can even begin to sell like Delcath (Nasdaq: DCTH) had to do for years, Calmare received 510k marketing clearance from the FDA in 2009 and, therefore, is permitted to sell in the US and begin building revenue and profits. In addition, the Calmare technology has the CE Mark, which is required for selling medical technology in the European Union and various other countries outside the EU.

The company has been successful in selling Calmare with sales of 77 units in the first six months of 2011, but there is even a greater expectation that with with insurance reimbursement and the news of the US Military order, there will be a ramping up of orders from clinics and medical centers.

Insurance Reimbursement and CPT Code

What will really drive future sales and interest by potential acquirers for Calmare is when there is broad insurance reimbursement of Calmare treatments. And that reimbursement may finally be coming. Up to now, the physicians purchasing Calmare for their medical practice have been entrepreneurial "fee for service" medical professionals who have evaluated the technology over a period of months with their own patients and have witnessed the positive results. However, it is understandable that many physicians and medical centers will wait for reimbursement approval and/or more clinical studies on the efficacy of Calmare. Although some insurance companies have fully or partially reimbursed for Calmare treatments already, these claims have been handled and approved on a case by case basis so far.

However, a long awaited CPT III code was assigned July 1st and will be effective January 1st. As defined by the American Medical Association, "Category III CPT codes are a temporary set of tracking codes for new and emerging technologies. These codes are intended to facilitate data collection on and assessment of new services and procedures. The Category III codes are intended for data collection purposes in the FDA approval process or to substantiate widespread usage."

The new CPT code is:" 0278T Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes)."

The AMA continues with the definition of the CPT III code:

However, the assignment of a CPT Category III code to a service does not indicate that it is experimental or of limited utility, but only that the service or technology is new and is being tracked for data collection. In the Final Rule for the 2002 Medicare Physician Fee Schedule (Federal Register, Thursday, November 1, 2001), the Center for Medicare and Medicaid Services (CMS) stated that they believed that Category III codes will serve a useful purpose and that payment for the service is at the discretion of the Carriers, but that the codes could be paid after entered into the computer systems. Local payment determination is reasonable for Category III CPT codes. It is not reasonable to categorically deny payment for CPT Category III codes since they are effectively more specific, more functional versions of unlisted codes which many payers cover with appropriate documentation.

The AMA continues:

Once payment policies are established of a Category III Code, the need for documentation will be minimized since Category III Codes are associated with unique and specific descriptions of the service or procedure. Since Category III codes are part of the CPT code set, all health care payers must be able to accept Category III codes into their systems to comply with the standards for transactions and code sets under HIPAA.

With clinical studies pending and more claims applications being filed for Calmare treatments with insurance companies, it is not overly optimistic (in the opinion of this author) to expect automatic insurance reimbursement in early 2012.

Clinical Studies and Peer-reviewed Articles

As for clinical studies, there currently are a number studies being conducted at the Mayo Clinic, University of Wisconsin Carbone Center and the Massey Cancer Center at the Virginia Commonwealth University-- including evaluating the efficacy of Calmare in the treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN). The following links will provide details of each trial:

Massey Cancer Center at Virgina Commonwealth University

Mayo Clinic (5 studies being conducted or currently being set up)

University of Wisconsin (UW) Carbone Center

A more layman-friendly notice of the UW study is in its recent newsletter, found HERE (Right column, center of page)

Additionally, Calmare has been the subject of a number of peer-reviewed articles in the Journal of Pain and Symptom Management, as published in the JPSM Journal.

International Distributors

A "dark horse" potential for additional sales comes courtesy of the Korea Food & Drug Administration (KFDA), which has authorized sales of the Calmare(R) medical device in the Republic of Korea. CTTC's partner, GEOMC Co., Ltd. of Seoul, South Korea, has expanded its relationship beyond just manufacturing the Calmare and is now the distributor in that country. A significant side note is that KFDA approval to sell a medical device includes insurance reimbursement approval.

Additional international distributors are expected to be named in the near future.

Media Coverage has been Growing

A recent feature story which aired on KSL-TV and was published in the Deseret News highlighted the success of Calmare in the treatment of a teenager who had suffered from severe pain from a nerve disorder called reflex neurovascular dystrophy, or RND, for nearly two years.

Another TV segment, from ABC News, out of Rhode Island, highlighted another patient's experience with Calmare/Scrambler in the treatment of her Complex Regional Pain Syndrome.

Capital Structure and Valuation

With only 14.2 million shares outstanding and a public float of only 13.4 million shares, CTTC's market cap is less than $19 million. The question that arises is what market cap would be reasonable to an acquiring company if Calmare technology receives broader insurance reimbursement, which would most likely trigger a substantial rise in revenue and profits? Would a $200 million market cap be a possibility--equating to over $15/share (assuming the same number of shares outstanding)? Would Stryker think $300 million too expensive a move to fill out its medical devices? Considering that the multi-billion dollar market in the treatment of chronic pain continues to expand as the overall US population ages, the market opportunity for an effective therapy using no pain medications and not requiring surgery is substantial.

Summary

Small companies with revolutionary new therapies/technologies that are effective oftentimes struggle with skepticism from the medical and the investment world. But for those companies fortunate enough to be introducing a new technology that can bear the scrutiny of clinical studies and eventually obtain insurance reimbursement, the returns to early investors can be significant as more media coverage and exponential revenue increases attract more investor interest. It would not be surprising if one or all of the Big Three in surgical pain relief implants-- Boston Scientific, Stryker and Medtronic-- could have Calmare and CTTC on their radar screens in the future as the technology meets with more success in the marketplace and with insurance reimbursement.

http://seekingalpha.com/article/293857-medical-device-companies-may-have-eyes-on-non-invasive-alternative-technology

[BB_PRO]

Looking to add in the 5's hopefully. Taking hits all over the place, soon to bounce IMO

[BB_PRO]

Stock to be in for the long haul. Added here

[mlkrborn]

Boston Scientific announces five-year, $150 mln investment in China to accelerate commercial expansion (BSX) 6.90 : Co announces a new investment that will support the establishment of a local, wholly owned manufacturing facility focused on serving Chinese market needs and developing a world-class training center for Chinese healthcare providers. The training facility will offer instruction on the latest medical device procedures, utilizing therapy-oriented education and a leading-edge, virtual learning, device simulation environment. As a result of this increased investment, as well as current and anticipated initiatives, co now expects to increase its revenues in China to more than $500 mln exiting 2016. The co estimates that its target market in China currently exceeds $1 bln and is growing ~20% annually.

[DewDiligence]

Shocker—JNJ pulls out of drug-eluting-stent business: #msg-64256077.

[EquityTrader]

Wants to come back up. 3-4 days tops before it hits $7.40

JUNE $7 options are the opportunity here.

http://investorshub.advfn.com/boards/board.aspx?board_id=14664

[alresa]

I hope you are right. I actually sold the shares in my wifes IRA but still hold a good chunk. Things were definitely looking better before this announcement. Not sure why this was such a big deal

[EquityTrader]

Taking advantage of the news of the CEO retiring. Turnaround expert lasted 2 years at BSX...BSX has gone through a lot over those 2 years including losing some of it's key staff due to a reprimand. Today is a gift IMO....get in at $7 and ride it back to $8 or hold on longer for $10+

Feel free to hit up the BIG BOARD and let me know your feelings too.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62934636

[alresa]

BSX had a decent earnings report. Trying to decide what to do. Sell outright, sell covered calls against my position, sell OTM puts.

[timvic]

BSX formed a Above The Stomach pattern.
Commodity Channel Index (CCI) is bullish for BSX.
Money Flow Index (MFI) is bullish and moving up for BSX.
The 10-day simple moving average is bearish and moving down for BSX.
Average volume increase over 5% for BSX.
Stock performance base on day of week in the past 90 days.
Monday: -0.10%
Tuesday: 4.49%
Wednesday: -14.31%
Thursday: 8.23%
Friday: -4.06%
Next Earnings Release Date: 04/25/11.

[alresa]

BSX - real strong the last couple of days. Question is will it continue next week

[TRENDmendous]

BSX $6.97 and the Damn Feb 19 7.0 Calls are still .13 x .14... Go figure!

[RaisingKahne]

BSX 6.82

[mlkrborn]

Yep! It is time ..

[alresa]

Good week for BSX with earnings and improved guidance. Ready to add more in the next couple of weeks

[mlkrborn]

Boston Scientific Corp. said Tuesday it's launching a clinical trial to study a new type of drug-coated stent.---A MONTH ? old news..

The device, dubbed Synergy, features a biodegradable coating and aims to address some concerns associated with earlier generations of drug-coated stents.

Stents are tiny mesh tubes used to prop open clogged arteries. Some versions of the devices are coated with drugs that help prevent the formation of scar tissue. However, there is some evidence that drug-coated stents increase the risk that a patient will develop dangerous clots.

Boston Scientific's Synergy stent differs from earlier technologies, as the coating degrades over time, leaving behind a bare-metal stent.

The clinical trial will test the product on 291 patents in Australia, Europe and New Zealand.

Boston Scientific (NYSE: BSX) is based in Natick, Mass., but has major operations in Arden Hills and Maple Grove. It develops and manufactures stents in Minnesota.


Read more: Boston Scientific to study new stent - Minneapolis / St. Paul Business Journal

[mlkrborn]

BSX's stent news good news yet the competitor beats it in a 2 year study:
Abbott stent tops Boston Sci's at two years -study - Reuters, 4:34:00 AM
Boston Scientific's TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
Date : 09/22/2010 @ 1:01PM
Source : PR Newswire
Stock : Boston Scientific (BSX)
Quote : 5.585 -0.035 (-0.62%) @ 12:31PM


Boston Scientific's TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
Boston Scientific (NYSE:BSX)
Intraday Stock Chart

Today : Thursday 23 September 2010
Click Here for more Boston Scientific Charts.

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients. Analysis of the data was presented by Louis A. Cannon, M.D., of the Cardiac and Vascular Research Center of Northern Michigan in Petoskey, Michigan, and Co-Principal Investigator of the PERSEUS clinical program, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, D.C.

"The PERSEUS diabetic subset data showed that the TAXUS Element Stent mitigated the impact of diabetes as a risk factor for restenosis following stenting procedures in the patients studied," said Dr. Cannon. "At one year, no significant differences in measures of stent efficacy were observed between the two patient groups. Diabetic status was not a predictor of re-intervention in patients treated with the TAXUS Element Stent."

The PERSEUS diabetic analysis included clinical outcomes at one year among 314 diabetic patients and 852 non-diabetic patients treated with the TAXUS Element Stent from the PERSEUS Workhorse and Small Vessel clinical trials. Due to significant disparity in baseline characteristics between diabetic and non-diabetic patients, propensity score analysis was used to allow for adjustment of baseline differences (other than the presence of diabetes) between the two groups.

Results showed that the TAXUS Element Stent maintained comparable rates of TLR at one year, whether adjusted or unadjusted, in the diabetic and non-diabetic patient populations (5.5 percent vs. 4.1 percent, p=0.43, adjusted). The adjusted and unadjusted rates of target lesion failure (TLF) at one year (defined as ischemia-driven TLR, or MI/cardiac death related to the target vessel) were also similar between the patient groups (7.5 percent vs. 5.4 percent, p=0.31, adjusted). Adjusted one-year rates of MACE, cardiac death, MI and ARC(1) definite/probable stent thrombosis showed no differences between the two populations (p-values of 0.14, 0.12, 0.38, and 0.77, respectively).

Nine-month adjusted angiographic outcomes showed similar in-segment late loss in diabetics and non-diabetics (0.23 mm vs. 0.19 mm, p=0.52). Rates of late loss for the TAXUS Element Stent were numerically lower than rates in prior studies for the TAXUS Express® and TAXUS Liberte® Stents(2).

"The PERSEUS diabetic analysis reinforces the historically consistent performance of paclitaxel in diabetic patients compared to non-diabetic patients," said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific's Cardiology, Rhythm and Vascular Group. "The paclitaxel-based TAXUS Element Stent has a unique mechanism of action that helps inhibit restenosis across a wide variety of patients with coronary artery disease."

The TAXUS Element Stent leverages the performance advantages of the Element platform with a decade of clinical success from the TAXUS program. The novel stent architecture and proprietary platinum chromium alloy combine to offer greater radial strength and flexibility. The stent architecture helps create consistent lesion coverage and drug distribution while improving deliverability, which is enhanced by an advanced catheter delivery system. The higher density alloy provides superior visibility and reduced recoil while permitting thinner struts compared to prior-generation stents(3).

"We are pleased to see the strong performance of the TAXUS Element Stent in both the overall population of the PERSEUS trial and the diabetic patient subset," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific. "As the worldwide prevalence of diabetes continues to increase dramatically, these findings are very encouraging for physicians and their patients."

Diabetes is generally associated with an increased risk of cardiovascular events and patients with diabetes are more likely than non-diabetic patients to require repeat procedures due to a higher incidence of restenosis following angioplasty and stenting.

In March, the Company announced one-year results from its PERSEUS clinical program demonstrating positive safety and efficacy outcomes for the TAXUS Element Stent System compared to prior-generation Boston Scientific stents in more than 1,486 patients in two parallel trials at 90 centers worldwide.

The TAXUS Element Paclitaxel-Eluting Stent System received CE Mark approval in May, which included a specific indication for the treatment of diabetic patients. The Company received CE Mark approval for the PROMUS® Element™ Everolimus-Eluting Stent System in October 2009. Both Element systems incorporate the same platinum chromium alloy, innovative stent design and advanced catheter delivery system.

The Company expects U.S. Food and Drug Administration approval for the TAXUS Element Stent System(4) in mid 2011 and for the PROMUS Element Stent System in mid 2012. In Japan, the Company expects approval for the TAXUS Element Stent System in late 2011 or early 2012 and for the PROMUS Element Stent System in mid 2012.

In the U.S., the TAXUS Element (ION) Stent and the PROMUS Element Stent are investigational devices and are limited by applicable law to investigational use only and are not available for sale.

[Bull Trader]

i think we see 6 here before end of the week....

[mlkrborn]

BSX 5.45

[mlkrborn]

BSX up a bit on news it may sell its pain killer..

[alresa]

I think that this is about ready to turn. Long time holder from about $12 recently double my position. Plan on adding more soon and ride this up (hopefully).

[mlkrborn]

BSX: 5.85!

[mlkrborn]

Boston Scientific Faces Sales Hit, But Image Another Issue
Date : 03/15/2010 @ 5:55PM
Source : Dow Jones News
Stock : Boston Scientific Corp. (BSX)
Quote : 6.8 -0.98 (-12.60%) @ 7:58PM


Boston Scientific Faces Sales Hit, But Image Another Issue

By Jon Kamp
Of DOW JONES NEWSWIRES


ATLANTA (Dow Jones)
Physicians at a major heart conference were surprised Monday by news Boston Scientific Corp. (BSX) suspended implantable defibrillators shipments because of paperwork problems, another hit to the company's already fragile reputation.

The news will likely hurt Boston Scientific's sales, but patients shouldn't feel any impact, as long as this remains a clerical problem, doctors said.

Boston Scientific said Monday that it failed to submit some manufacturing process changes for Food and Drug Administration approval. The company declined to describe the process changes that sparked its dramatic move, other than to say they are well-established and validated.

"It strikes me as a very huge response to a minor book-keeping problem," said Douglas Zipes, an electrophysiologist at Indiana University Medical Center, who doesn't have ties to Boston Scientific. These doctors implant devices like defibrillators, which help guard against potentially deadly rhythm problems.

There is little question the recall will hurt business, as evidenced by Boston Scientific's 12.6% stock slide to $6.80, the lowest close in about a year, but doctors at the American College of Cardiology conference didn't see an immediate effect on patients. It isn't hard to substitute other products, in this cases defibrillators from Medtronic Inc. (MDT) and St. Jude Medical Inc. (STJ), they said.

Also, Boston Scientific pegged the matter to a clerical problem, not a clinical one.

"I don't think our patients are going to suffer because we've got alternatives," Zipes said.

Nonetheless, the issue is disruptive, because many hospitals are tied to certain device companies through contracts, said Ralph Brindis, a general cardiologist at Oakland Medical Center and president-elect of ACC. Then again, "you can imagine other companies would want to fill the void," Brindis said.

Many hospitals also contract with multiple companies in an industry with a history of product problems and supply disruptions. Those include major product troubles at Guidant Corp. in 2005, before Boston Scientific bought the company, and Medtronic's recall in 2007 of faulty cables that connect defibrillators to the heart.

Shares of Boston Scientific rivals jumped on expectations for business gains. St. Jude, which depends the most on defibrillator sales, traded up 8.2% to $40.56, while Medtronic, the heavyweight in the roughly $6 billion defibrillator market, gained 4.3% to close at $45.81.

Citigroup analyst Matt Dodds said a five percentage-point market share loss for Boston Scientific seems possible, and that market growth in general could slow. "We can't remember the last time there has been a recall so wide in scope," Dodds said.

The move comes four years after Boston Scientific bought into the defibrillator business by acquiring the damaged Guidant franchise. The Natick, Mass., company has worked ever since to restore a business marred by product recalls and allegations Guidant was slow to disclose problems--and doctors give Boston Scientific credit on that front--but the stoppage represents a big setback.

"I really had hoped they were back," said George Crossley, an electrophysiologist with a hospital system in Tennessee who also doesn't have company ties. "They've put in an enormous amount of effort into really recreating the quality there."

Boston Scientific is scheduled to go before an FDA panel on Thursday to review the company's bid to expand usage of expensive heart-failure defibrillators. This is based on a recently successful major study Boston Scientific funded.

Arthur Moss, a cardiologist at the University of Rochester who headed that study, and will take part in Thursday's presentation, said the sales stoppage news "came as a total surprise."

Boston Scientific resolved three years ago an FDA "warning letter" it inherited with Guidant. That allowed the company to once again get new products on the market, including two defibrillators with very thin cases that have helped it regain some footing.

The company recently redesigned the plastic caps on those devices amid isolated signs they can weaken when placed under chest muscles, which is rare in the U.S., rather than just under the skin. An article published in a medical journal recently cited one case of a problem with an under-the-skin implant, but Boston Scientific has strongly refuted there was an issue specific to its device.

The stoppage to defibrillator shipments affects a wider range of products, however.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; [e-mail]

[mlkrborn]

$7.30S after reporting:
("Boston Scientific Loss Narrows; Company Rebuts Article," published at 6:03 p.m. EST Wednesday, failed to note that the percentage of jobs to be cut were just its non-manufacturing work force. The story also misstated the low end of Boston Scientific's 2010 revenue forecast. A corrected story follows.)


DOW JONES NEWSWIRES


Boston Scientific Corp.'s (BSX) fourth-quarter loss narrowed as charges shrank despite a big settlement in the latest period, but the medical-device maker shook up management and plans to streamline operations.

The company also rebutted an article in the journal HeartRhythm that indicated a key bond in the Cognis defibrillator could weaken.

"We find it unacceptable that HeartRhythm rushed this manuscript to publication and speculated on the cause of the problem without requesting from us a detailed engineering analysis of the explanted device," the company said in a prepared statement, adding that it found the device performed normally in the patient despite what it acknowledged was a weakened bond.

Separately, Boston Scientific said its restructuring plan will combine the cardiovascular and cardiac-rhythm groups and eliminate its international headquarters, among other measures. Overall, the company will cut 1,000 to 1,300 positions, or 8% to 10% of its nonmanufacturingwork force. Pretax charges will amount to $180 million to $200 million, mostly cash.

Among the biggest management changes, Chief Financial Officer Sam Leno will move over to chief operations officer. Chief Accounting Officer and Controller Jeff Capello will become chief financial officer. In addition, Cardiac Rhythm Management Group head Fred Colen will take on the new position of chief technical officer.

Boston Scientific also said it expects adjusted earnings of 62 cents to 72 cents on revenue of $8.1 billion to $8.5 billion. The earnings view tops the 57 cents expected by Wall Street, though the revenue is mostly below the $8.43 billion analyst projection.

The first-quarter view follows a similar pattern, with the company seeing adjusted earnings of 13 cents to 17 cents a share and revenue of $2 billion to $2.1 billion. Analysts expect 13 cents and $2.07 billion, respectively.

Aside from broader concerns about belt-tightening at hospitals, Boston Scientific has taken hits from patent settlements, most recently with a $1.73 billion pact with Johnson & Johnson (JNJ). However, Elliott shrugged off that impact Wednesday.

The litigation settlement announced last week with Johnson & Johnson is part of our ongoing effort across the company to reduce risk," said President and Chief Executive Ray Elliott. "We have the financial strength and flexibility to meet this obligation with no appreciable impact on our debt covenants and still retain significant liquidity."

Boston Scientific reported a loss of $1.08 billion, or 71 cents a share, compared with $2.39 billion, or $1.59 a share, a year earlier. Excluding charges related to the settlement, restructuring and other items, per-share earnings were flat at 20 cents.

Net sales climbed 3.8% to $2.08 billion. Excluding currency translation and sales from divested businesses, sales were flat.

In October, the company projected per-share earnings of 17 cents to 21 cents on revenue of $2.03 billion to $2.13 billion.

"Endoscopy, Urology/Gynecology and Neuromodulation posted excellent growth, and we maintained our clear leadership in the global drug-eluting stent market," said Elliott.

Gross margin narrowed to 65.8% from 68.5%.

Worldwide sales of the company's stents--tiny metal scaffolds used to prop open heart arteries--decreased 4.8%, with revenue down 13% in the U.S. and up 3.9% abroad.

Sales of Boston Scientific's stents have been closely watched since two studies showed an Abbott Laboratories (ABT) heart stent worked better.

Sales of heart-rhythm management devices--including implantable cardioverter defibrillators, or ICDs--grew 6.1% worldwide, as U.S. sales rose 1.5% and sales abroad were up 16%.

Rival St. Jude Medical Inc. (STJ) said two weeks ago it swung to a fourth-quarter profit and expects 12% to 14% earnings growth this year, with improvements coming in pacemakers and defibrillators.

Boston Scientific shares were up 2.3% to $8.10 in late trading. The stock is down slightly over the past year.

-By Jay Miller, Dow Jones Newswires; 212-416-2355; [e-mail]




Bookmark With :
Facebook MySpace Twitter Digg Del.icio.us StumbleUpon Reddit Google Bookmarks Newsvine Technorati Furl AIM Slashdot Yahoo

[musicalchairs]

The hit to the books will be taken for 3rd Q. Next Q will be back in the $

By MarketWatch
Nov 6, 2009 09:01:09 (ET)

(8:50 AM ET) BOSTON (MarketWatch) -- Boston Scientific Corp.(BSX, Trade )said Friday that it has agreed in principle to settle an investigation with the Department of Justice for $296 million. The probe focused on the former Guidant Corp.'s 2005 warnings on its Contak Renewal and Ventak Prizm medical device products. Boston Scientific acquired Guidant in 2006. Under the settlement, Guidant will plead to two misdemeanor charges of failing to supply certain information to U.S. regulators. Boston Scientific said the payment will be recorded retroactively as a charge in the third-quarter. As a result of the charge, the company has restated its third-quarter earnings report to show a loss of $94 million, or 6 cents a share. Previously, the company had reported a profit of $200 million, or 13 cents a share.

[musicalchairs]

It's been a week now and no action. Still looking for movement........

This is a safe bet. They WILL make the changes necessary to boost profit before the next report.

IMO

[DominaDoom]

This is such an awesome play.

[musicalchairs]

This is the bad news report on a down day at the street. No doubt BSX will take measures to restore profit to the bottom line. Nice time to jump in..........

Shares of Boston Scientific Corp. ($8.46, -$1.70, -16.73%) dropped after the company pointed to challenges facing markets for its top heart devices, implantable defibrillators and drug-coated stents. The company issued weaker results than Wall Street expected late Monday while it sliced its full-year earnings guidance. On a long conference call Tuesday, the company noted pressure on device prices and the potential negative impact of recent stent studies, plus a softened growth outlook within the market for heart-rhythm devices. Shares of St. Jude Medical Inc. (STJ, $32.50, -$1.78, -5.19%) also fell. -Dow Jones

[musicalchairs]

Can't believe I'm the first here. With the huge drop in value of this solid company due to a single downgrade I would think there would be a buzz about it. This is a healthcare stock people!